Below are the best information and knowledge on the subject hpv e6 e7 positive treatment compiled and compiled by our own team alltopus:
1. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Date Submitted: 08/18/2019 03:19 AM
Average star voting: 5 ⭐ ( 35220 reviews)
Summary: Human papillomavirus (HPV)-induced cervical cancer is a major health issue among women from the poorly/under-developed sectors of the world. It accounts for a high mortality rate, because of its late diagnosis and poor prognosis. Initial establishment and subsequent progression of this form of cancer is completely dependent on two major oncogenes E6 and E7, which is expressed constitutively leading to tumorigenesis. Thus, manipulation of these genes represent the most successful form of cervical cancer therapy. In the present article information on structural, functional and clinical dimensions of E6 and E7 activity have been reviewed. The genome organisation and protein structure of E6 and E7 have been discussed followed by their mechanism to establish the six major cancer hallmarks in cervical tissues for tumour propagation. The later section of this review article deals with the different modes of therapeutics which function by deregulating E6 and E7 activity. Since E6 and E7 are the biomarkers of a cervical cancer cell and are the ones driving the cancer progression, therapeutic approaches targeting E6 and E7 have been proved to be highly efficient in terms of focused removal of abnormally propagating malignant cells. Therapeutics including different forms of vaccines to advanced genome editing techniques which suppress E6 and E7 activity have been found to successfully bring down the population of cervical cancer cells infected with HPV. T-cell mediated immunotherapy is another upcoming successful form of treatment to eradicate HPV infected tumorigenic cells. Additionally, therapeutics using natural compounds from plants or other natural repositories, i.e. phytotherapeutic approaches have also been reviewed here, which prove their anticancer potential through E6 and E7 inhibitory effects. Thus, E6 and E7 repression through any of these methods is a significant approach towards cervical cancer therapy, described in details in this review along with an insight into the signalling pathways and molecular mechanistic of E6 and E7 action.
Match with the search results: Thus, E6 and E7 repression through any of these methods is a significant approach toward cervical cancer therapy, described in details in ……. read more
2. HPV-Based Screening, Triage, Treatment, and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia
Date Submitted: 07/22/2020 11:54 AM
Average star voting: 3 ⭐ ( 23926 reviews)
Summary: Cervical cancer is the second most common cause of death from cancer in women worldwide, and the development of new diagnostic, prognostic, and treatment strategies merits special attention. Many efforts have been made to design new drugs and develop immunotherapy and gene therapy strategies to treat cervical cancer. HPV genotyping has potentially valuable applications in triage of low-grade abnormal cervical cytology, assessment of prognosis and followup of cervical intraepithelial neoplasia, and in treatment strategies for invasive cervical cancer. It is known that during the development of cervical cancer associated with HPV infection, a cascade of abnormal events is induced, including disruption of cellular cycle control, alteration of gene expression, and deregulation of microRNA expression. Thus, the identification and subsequent functional evaluation of host proteins associated with HPV E6 and E7 oncoproteins may provide useful information in understanding cervical carcinogenesis, identifying cervical cancer molecular markers, and developing specific targeting strategies against tumor cells. Therefore, in this paper, we discuss the main diagnostic methods, management strategies, and followup of HPV-associated cervical lesions and review clinical trials applying gene therapy strategies against the development of cervical cancer.
Match with the search results: HPV E6 and E7 oncoproteins are excellent candidates for HPV therapeutic vaccination strategies, and the most of the therapeutic vaccines that have been tested ……. read more
3. Triage of Women with Minor Cervical Lesions: Data Suggesting a “Test and Treat” Approach for HPV E6/E7 mRNA Testing
Date Submitted: 12/29/2020 07:53 PM
Average star voting: 5 ⭐ ( 53786 reviews)
Summary: Background Human papillomavirus (HPV) testing is included in the cervical cancer screening program in the triage of women with equivocal (ASC-US) or low-grade (LSIL) cytological lesions. These women have an increased risk for developing high grade dysplasia and cancer (CIN2+) compared to women with normal cytology. However, in order to avoid unnecessary follow-up, as well as overtreatment, a high positive predictive value (PPV) of the triage test is important. Methodology/Principal Findings The HPV test PreTect HPV-Proofer, detecting E6/E7 mRNA from the HPV types 16, 18, 31, 33 and 45, is used as triage test together with repeat cytology. PPV data for HPV E6/E7 mRNA testing during the period from January 2006 up to June 2009 are reported. In total, 406 of 2099 women (19.3%) had a positive HPV test result. Of the women with a positive test result and with a histological diagnosis (n = 347), 243 women had histological high-grade dysplasia or cancer (CIN2+), giving a PPV of 70.0% (95% confidence interval [CI], 65.2%–74.8%). For HPV 16 or HPV 33 positive women above 40 years of age, the PPV was 83.7% (95% CI, 73.3%–94.0%) and 84.6% (95% CI, 65.0%–100.0%) respectively. The PPV of test positive women with HSIL cytology was 94.2% (95% CI, 88.7%–99.7%). Conclusions When the result in triage is HPV mRNA positive, our data suggest direct treatment for women above 40 years of age or for women with a concurrent cytological HSIL diagnosis, contributing to better clinical safety for these women. In addition, by decreasing the time to treatment, thereby reducing the number of recalls, the patient management algorithm will be considerably improved, in turn reducing follow-up costs as well as unnecessary psychological stress among patients.
Match with the search results: Conclusions When the result in triage is HPV mRNA positive, our data suggest direct treatment for women above 40 years of age or for women ……. read more
4. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Date Submitted: 01/09/2019 02:10 PM
Average star voting: 3 ⭐ ( 27701 reviews)
Match with the search results: Therapeutics including different forms of vaccines to advanced genome editing techniques, which suppress E6 and E7 activity, have been found to ……. read more
5. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer | Cancer Gene Therapy
Date Submitted: 01/06/2019 03:23 AM
Average star voting: 3 ⭐ ( 88737 reviews)
Summary: Persistent infection by high-risk types of human papillomaviruses (HPV) is a necessary cause of cervical cancer, with HPV16 the most prevalent, accounting for more than 50% of reported cases. The virus encodes the E6 and E7 oncoproteins, whose expression is essential for maintenance of the malignant phenotype. To select efficacious siRNAs applicable to RNAi therapy for patients with HPV16+ cervical cancer, E6 and E7 siRNAs were designed using siDirect computer software, after which 10 compatible with all HPV16 variants were selected, and then extensively examined for RNAi activity and specificity using HPV16+ and HPV16−cells. Three siRNAs with the highest RNAi activities toward E6 and E7 expression, as well as specific and potent growth suppression of HPV16+ cancer cells as low as 1 nM were chosen. Growth suppression was accompanied by accumulation of p53 and p21WAF1/CIP1, as well as morphological and cytochemical changes characteristic of cellular senescence. Antitumor activity of one of the selected siRNAs was confirmed by retarded tumor growth of HPV16+ cells in NOD/SCID mice when locally injected in a complex with atelocollagen. Our results demonstrate that these E6 and E7 siRNAs are promising therapeutic agents for treatment of virus-related cancer.
Match with the search results: Most HPV infections go away on their own. If not, don’t worry. While there’s no cure for the virus, there are treatments for the problems HPV can cause….. read more
6. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors | Cancer Gene Therapy
Date Submitted: 04/19/2020 10:17 AM
Average star voting: 4 ⭐ ( 27057 reviews)
Summary: Human papillomaviruses (HPVs) are the causative factor for >90% of cervical cancers and 25% of head and neck cancers. The incidence of HPV positive (+) head and neck squamous cell carcinomas has greatly increased in the last 30 years. E6 and E7 are the two key viral oncoproteins that induce and propagate cellular transformation. An immune response generated during cisplatin/radiation therapy improves tumor clearance of HPV(+) cancers. Augmenting this induced response during therapy with an adenoviral HPV16 E6/E7 vaccine improves long-term survival in pre-clinical models. Here, we describe the generation of an HPV16 E6/E7 construct, which contains mutations that render E6/E7 non-oncogenic, while preserving antigenicity. These mutations do not allow E6/E7 to degrade p53, pRb, PTPN13, or activate telomerase. Non-oncogenic E6/E7 (E6Δ/E7Δ) expressed as a stable integrant, or in the [E1-, E2b-] adenovirus, lacks the ability to transform human cells while retaining the ability to induce an HPV-specific immune response. Moreover, E6Δ/E7Δ plus chemotherapy/radiation statistically enhances clearance of established HPV(+) cancer in vivo.
Match with the search results: There is no medical treatment for HPV infections, but the cervical … Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis….. read more
7. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker – BMC Cancer
Date Submitted: 05/04/2020 05:56 AM
Average star voting: 5 ⭐ ( 12394 reviews)
Summary: The aims of this study were to detect HPV E6/E7 mRNA expression in women with high-risk genotypes (HPV-16, -18, -31, -33 and -45) analysing its relationship with tissue pathology and 2) 2-year follow-up of E6/E7 mRNA tested group. Our samples were genotyped and classified by pathologists according to Bethesda system. After RNA extraction, E6/E7 oncogene mRNA detection was performed by NucliSens® EasyQ® HPV v1 Test (bioMérieux). The results of the present study showed that E6/E7 mRNA positivity rate was 68.29 % in women tested once and 69.56 % in women tested twice. According to tissue pathology, all samples with high-grade lesions were positive for mRNA. Among women with low-grade lesions varied over the years from 89.28 to 84 % in women tested once and from 77.77 to 70 % in tested twice. Among women without lesion, positivity rate maintained in women tested once (from 50 to 41.38 %) and decreased in tested twice, from 63.63 to 44.44 %. Regarding lesion evolution, mRNA positivity was higher in women with lesion progression (53.13 %) and in women with positive results in two tested samples (83.33 %). HPV E6/E7 mRNA detection may be an effective screening test and biomarker for cervical cancer in women infected with these five genotypes. Nonetheless, further studies are needed to standardize as routine triage test.
Match with the search results: And head and neck, cervical, anal, and genital cancers can be treated, too. Testing for HPV. What’s the difference between an HPV test and a Pap ……. read more
8. Human papillomavirus E6E7 mRNA and TERC lncRNA in situ detection in cervical scraped cells and cervical disease progression assessment – Virology Journal
Date Submitted: 12/09/2021 07:16 AM
Average star voting: 3 ⭐ ( 34264 reviews)
Summary: Human papillomavirus screen in female cervical cells has demonstrated values in clinical diagnosis of precancerous lesions and cervical cancers. Human papillomavirus tests of cervical cells by utilizing Polymerase Chain Reaction (PCR) method provides human papillomavirus infection status however no further virus in situ information. Although it is well known that the tests of human papillomavirus E6/E7 RNA location in infected cervical cells and cell internal malignancy molecular will provide clues for gynecologists to evaluate disease progression, there are technique difficulties to preserve RNAs in cervical scraped cells for in situ hybridization. In current study, after developing a cervical cell collection and preparation method for RNA in situ hybridization, we captured the chance to screen 98 patient cervical cell samples and detected human papillomavirus E6/E7 mRNAs of high-risk subtypes, low-risk subtypes and long non-coding RNA (lncRNA) TERC in the cells. There were 69 samples exhibited consistence between human papillomavirus PCR and human papillomavirus RNA in situ hybridization results in cervical collected cells. Among them, 23 were both positive and 46 were both negative. In the rest 29 samples, 8 were HPV RNAscope positive, either high risk or low risk subtypes, however HPV PCR negative. Another 9 samples were HPV PCR results positive whereas RNAscope negative. The last 12 samples were HPV positive detected by both RNAscope and PCR methods, however inconsistent between high-risk and low-risk subtypes. In RNAscope positive samples, viral E6/E7 mRNAs were observed to distribute in cervical scraped cell nucleus and cytoplasm. Moreover, HPV viral RNA gathered clusters were observed outside of cells through human papillomavirus RNA in situ hybridization detection. Varied numbers of human papillomavirus infective cells were detected by RNAscope assay in different patients even though they were all human papillomavirus high-risk subtype positive discovered by human papillomavirus PCR results. A cell malignancy related long non-coding RNA, TERC, has been detected in seven patient samples. The patient follow-up information was further analyzed with RNAscope results which indicated a combination of RNAscope positive signals of TERC and human papillomavirus high risk signals in more than 10 cells (cytoplasm or nucleus) may connect with cervical lesion fast progression which deserves further studies in the future.C Taken together, current study has provided an observable clue for gynecologists to evaluate human papillomavirus infection stage and cell malignancy status which may contribute for assessment of cervical disease progression.
Match with the search results: HPV mRNA testing is based on pooled detection of HPV E6/E7 mRNA from high-risk types of HPV. The test is considered positive if HPV E6/E7 mRNA is above the ……. read more
9. Human Papillomavirus Disease | NIH
Date Submitted: 05/01/2020 05:28 PM
Average star voting: 3 ⭐ ( 27662 reviews)
Summary: Human papillomavirus (HPV) infection is the major risk factor for development of cervical cancer; find information on prevention, screening, and treatment here.
Match with the search results: The HPV test can help identify your risk of cervical cancer. … follow-up monitoring, further testing or treatment of abnormal cells….. read more
10. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer | Human Gene Therapy
Date Submitted: 12/07/2019 08:02 PM
Average star voting: 3 ⭐ ( 62778 reviews)
Match with the search results: If you get a positive HPV test, your physician has detected one or more high risk strains of the virus on the Pap test of your cervix. If the virus stays with ……. read more